Biolegend, 110730, PE/Cyanine7 anti-mouse CD45.1 Antibody, 100μg

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: SJL mouse thymocytes and splenocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, in vitro blocking of B cell responses1,2, immunohistochemical staining of frozen sections: OCT embedded7 and acetone-fixed4-6 (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).
Application References(PubMed link indicates BioLegend citation): Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block) Yakura H, et al. 1986. J. Immunol. 136:2729. (Block) Shen FW, et al. 1986. Immunogenetics 24:146. (IP) Suzuki K, et al. 2000. Immunity 13:691. (IHC-F) Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC-F) Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC-F) Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC-F) Pascal V, et al. 2007. J. Immunol. 179:1751. (FC) Mende I, et al. 2006. Blood 107:1383. (IHC-F, FC) Phan TG, et al. 2007. Nature Immunol. 8:992. (FC) Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed Pascal V, et al.2007. J. Immunol. 179:1751. PubMed Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed Li LX, et al. 2010. J. Immunol. 184:1728. PubMed Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations: Burghardt S, et al. 2013. J Immunol. 191:5574. PubMed Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed Giampaolo S, et al. 2023. iScience. 26:106234. PubMed Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed du Halgouet A, et al. 2023. Immunity. 56:78. PubMed Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed Zhou J, et al. 2019. Immunity. 50:403. PubMed Yu Y, et al. 2022. iScience. 25:105004. PubMed Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed Postat J et al. 2018. Immunity. 49(4):654-665 . PubMed Puiffe ML, et al. 2020. Front Immunol. 11:600012. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed Yamamoto R et al. 2018. Cell stem cell. 22(4):600-607 . PubMed Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed Liu Y, et al. 2021. Haematologica. Online ahead of print. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed Jia W, et al. 2021. Nat Commun. 12:2118. PubMed Wiedemann GM, et al. 2020. Cell Rep. 33:108498. PubMed Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed Yue X, et al. 2019. Nat Commun. 10:2011. PubMed Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed Geng S, et al. 2021. JCI Insight. 6:. PubMed Glaros V, et al. 2021. Immunity. 54:2005. PubMed Mansell E, et al. 2020. Cell Stem Cell. . PubMed Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed Ronsard L, et al. 2021. Front Immunol. 12:730471. PubMed Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed Gao Y, et al. 2020. Immunity. 52(6):1007-1021.e8. PubMed Subedi A, et al. 2021. Cell Stem Cell. :. PubMed Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed Severance AL, et al. 2022. iScience. 25:104400. PubMed Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed Reimer D, et al. 2020. Cell Reports. 32(6):108030. PubMed Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed Kwok T, et al. 2022. Front Aging. 3:838943. PubMed Kang YH, et al. 2019. Nat Commun. 10:912. PubMed Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed Ghezraoui H, et al. 2018. Nature. 560:122. PubMed Niven J, et al. 2019. Cell Rep. 28:21. PubMed Koide S, et al. 2022. iScience. 25:103603. PubMed Miyauchi K, et al. 2021. Nat Commun. 12:3789. PubMed Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed Wilkinson AC, et al. 2019. Nature. 571:117. PubMed Geary CD et al. 2018. Cell reports. 24(8):1949-1957 . PubMed Barrigan L, et al. 2013. Infect Immun . 81:2028. PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed Zhu Y et al. 2017. The Journal of Neuroscience. 37(9):2362-2376 . PubMed Subramanian S, et al. 2022. Nat Immunol. 23:458. PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
RRID: AB_1134170 (BioLegend Cat. No. 110729) AB_1134168 (BioLegend Cat. No. 110730)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45.1 on UniProt.org
Clone: A20
Regulatory Status: RUO
Other Names: T200, Ly-5.1, LCA
Isotype: Mouse (A.SW) IgG2a, κ